BACKGROUND: @entity64725 /SR90107A, a synthetic @entity23868 , is a selective inhibitor of @entity6236 . It was hypothesized that prolonged @entity6236 inhibition with @entity23868 may be an effective and safe antithrombotic co-therapy in acute @entity583 . METHODS AND RESULTS: @entity1 (n=333) with evolving ST-segment elevation acute @entity583 were treated with @entity117 and alteplase and randomized to unfractionated heparin, given intravenously during 48 to 72 h, or to a low, medium or high dose of @entity23868 , administered daily for 5 to 7 days, intravenously on the first day, then subcutaneously. Coronary angiography was performed at 90 min and on days 5 to 7. Thrombolysis in @entity583 (TIMI) flow grade 3 rates at 90 min were similar in the four treatment groups. Among @entity1 with TIMI 3 flow at 90 min and who did not undergo a coronary intervention (n=155), a trend towards less reocclusion of the infarct-related vessel on days 5 to 7 was observed with @entity23868 : 0.9% vs 7.0% with unfractionated heparin (P=0.065). Also, fewer revascularizations during the 30-day follow-up period were performed in @entity1 given @entity23868 (39% vs 51% for unfractionated heparin;P=0.054). The primary safety end-point, the combined incidence of @entity932 and need for blood transfusion, was identical with @entity23868 and unfractionated heparin (7.1%). One non-fatal @entity932 occurred in the 241 @entity1 given @entity23868 (0.4%). CONCLUSIONS: In this study, @entity23868 given together with alteplase was safe and as effective as unfractionated heparin in restoring coronary artery patency. Prolonged administration of @entity23868 was associated with a trend towards less reocclusion and fewer revascularizations. Selective @entity6236 -inhibition seems to be an attractive therapeutic concept in @entity1 presenting with ST-segment elevation acute @entity583 .

A synthetic XXXX inhibitor ( @entity64725 /SR9017A) as an adjunct to fibrinolysis in acute @entity583 . The PENTALYSE study.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity23868 :: ('CHEBI:35369', 'Chemical') :: ['pentasaccharide'] @entity932 :: ('MESH:D020300', 'Disease') :: ['intracranial haemorrhage'] @entity64725 :: ('MESH:C064764', 'Chemical') :: ['ORG31540'] @entity117 :: ('MESH:D001241', 'Chemical') :: ['aspirin'] @entity583 :: ('MESH:D009203', 'Disease') :: ['myocardial infarction', 'Myocardial Infarction'] @entity6236 :: ('2159', 'Gene') :: ['factor-Xa']
@entity6236 :: (2159,Gene) :: ['factor-Xa']
